Allogene Therapeutics Inc. (ALLO)
NASDAQ · Healthcare
Allogene Therapeutics Inc. EBITDA 2019–2025
Allogene Therapeutics Inc. annual/quarterly ebitda history and growth rate from 2019 to 2025. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Allogene Therapeutics Inc. ebitda for the quarter ending March 31, 2025 was -62.1 M, a 5.85% decrease year-over-year.
- Allogene Therapeutics Inc. annual ebitda for 2025 was -197.0 M, a 24.12% decrease from 2024.
- Allogene Therapeutics Inc. annual ebitda for 2024 was -259.6 M, a 17.22% decrease from 2023.
- Allogene Therapeutics Inc. annual ebitda for 2023 was -313.5 M, a 2.40% decrease from 2022.
- Allogene Therapeutics Inc. annual ebitda for 2022 was -321.2 M.
EBITDA
QUARTERLY · $B
Allogene Therapeutics Inc. EBITDA — FAQ
Allogene Therapeutics Inc. (ALLO) ebitda over the last 7 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see ALLO's ebitda history?
The chart and table above show Allogene Therapeutics Inc.'s ebitda by year and by quarter, including the growth rate.